51. Fluorine-18 labeling PEGylated 6-boronotryptophan for PET scanning of mice for assessing the pharmacokinetics for boron neutron capture therapy of brain tumors.
- Author
-
Chen XP, Hsu FC, Huang KY, Hsieh TS, Farn SS, Sheu RJ, and Yu CS
- Subjects
- Animals, Mice, Humans, Cell Line, Tumor, Boron Compounds chemistry, Boron Compounds pharmacokinetics, Boron Compounds chemical synthesis, Tryptophan chemistry, Tryptophan analogs & derivatives, Tryptophan pharmacokinetics, Tryptophan chemical synthesis, Molecular Structure, Boron Neutron Capture Therapy, Fluorine Radioisotopes chemistry, Positron-Emission Tomography, Polyethylene Glycols chemistry, Brain Neoplasms diagnostic imaging, Brain Neoplasms radiotherapy, Brain Neoplasms metabolism
- Abstract
Two tryptophan compound classes 5- and 6-borono PEGylated boronotryptophan derivatives have been prepared for assessing their aqueous solubility as formulation of injections for boron neutron capture therapy (BNCT). The PEGylation has improved their aqueous solubility thereby increasing their test concentration in 1 mM without suffering from toxicity. In-vitro uptake assay of PEGylated 5- and 6-boronotryptophan showed that the B-10 concentration can reach 15-50 ppm in U87 cell whereas the uptake in LN229 cell varies. Shorter PEG compound 6-boronotryptophanPEG200[
18 F] was obtained in 1.7 % radiochemical yield and the PET-derived radioradioactivity percentage in 18 % was taken up by U87 tumor at the limb of xenograft mouse. As high as tumor to normal uptake ratio in 170 (T/N) was obtained while an inferior radioactivity uptake of 3 % and T/N of 8 was observed in LN229 xenografted mouse., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF